Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.

Autor: Darcy Welch, Elliot Kahen, Brooke Fridley, Andrew S Brohl, Christopher L Cubitt, Damon R Reed

Publikováno v: PLoS ONE, Vol 14, Iss 9, p e0222228 (2019)

Ewing Sarcoma (ES) is characterized by recurrent translocations between EWSR1 and members of the ETS family of transcription factors. The transcriptional activity of the fusion oncoprotein is dependent on interaction with the nucleosome remodeling an

Externí odkaz: https://doaj.org/article/c3bbc978931f43f881e091e9cd886658

Data from Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression

Autor: Liewei Wang, Daniel Schaid, Matthew Ames, Michelle Hildebrandt, Stephanie Safgren, Anthony Batzler, Gregory Jenkins, Krishna Kalari, Brooke Fridley, Liang Li

Two cytidine analogues, gemcitabine (dFdC) and 1-β-d-arabinofuranosylcytosine (AraC), show significant therapeutic effect in a variety of cancers. However, response to these drugs varies widely. Evidence from tumor biopsy samples shows that expressi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f685898dfcdc9887a499df1e36c07152
https://doi.org/10.1158/0008-5472.c.6497606

Abstract P2-14-01: Phase II neoadjuvant trial of Interferon-gamma plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer

Autor: Hyo S Han, Ricardo Costa, Avan Armaghani, Aixa Soyano, Loretta Loftus, Hatem Soliman, Brooke Fridley, Junmin Whiting, Aiana Cerezo, Marilin Rosa, Martine Extermann, Hung Khong, Brian Czerniecki

Publikováno v: Cancer Research. 82:P2-14

Background: IFN-γ, a cytokine that plays diverse roles in innate and adaptive immunity, has been shown to be essential in anti-tumor immune response. In vitro and in vivo studies have shown the synergistic effect of IFN-γ in combination with HER2-t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::871cf17ea171b38857222bf9e2e56dee
https://doi.org/10.1158/1538-7445.sabcs21-p2-14-01

Phase II trial of gemcitabine and nab-paclitaxel for recurrent osteosarcoma: A report from the National Pediatric Cancer Foundation

Autor: Lars M. Wagner, Leo Mascarenhas, Michael Isakoff, Bhuvana Setty, Joanne P. Lagmay, Emi Caywood, Eric Stuart Sandler, Christine A. Pratilas, Scott C. Borinstein, Matteo M. Trucco, Brooke Fridley, Damon R. Reed, Javier E. Oesterheld

Publikováno v: Journal of Clinical Oncology. 40:10042-10042

10042 Background: The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. A retrospective study of 35 such patients has reported an objective response rate of 17% and 4-month progression-free survival

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1c3a40945377c202bfa22897c5a43eb1
https://doi.org/10.1200/jco.2022.40.16_suppl.10042

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data

Autor: Justin Guinney, Tao Wang, Teemu D Laajala, Kimberly Kanigel Winner, J Christopher Bare, Elias Chaibub Neto, Suleiman A Khan, Gopal Peddinti, Antti Airola, Tapio Pahikkala, Tuomas Mirtti, Thomas Yu, Brian M Bot, Liji Shen, Kald Abdallah, Thea Norman, Stephen Friend, Gustavo Stolovitzky, Howard Soule, Christopher J Sweeney, Charles J Ryan, Howard I Scher, Oliver Sartor, Yang Xie, Tero Aittokallio, Fang Liz Zhou, James C Costello, Catalina Anghe, Helia Azima, Robert Baertsch, Pedro J Ballester, Chris Bare, Vinayak Bhandari, Cuong C Dang, Maria Bekker-Nielsen Dunbar, Ann-Sophie Buchardt, Ljubomir Buturovic, Da Cao, Prabhakar Chalise, Junwoo Cho, Tzu-Ming Chu, R Yates Coley, Sailesh Conjeti, Sara Correia, Ziwei Dai, Junqiang Dai, Philip Dargatz, Sam Delavarkhan, Detian Deng, Ankur Dhanik, Yu Du, Aparna Elangovan, Shellie Ellis, Laura L Elo, Shadrielle M Espiritu, Fan Fan, Ashkan B Farshi, Ana Freitas, Brooke Fridley, Christiane Fuchs, Eyal Gofer, Gopalacharyulu Peddinti, Stefan Graw, Russ Greiner, Yuanfang Guan, Jing Guo, Pankaj Gupta, Anna I Guyer, Jiawei Han, Niels R Hansen, Billy HW Chang, Outi Hirvonen, Barbara Huang, Chao Huang, Jinseub Hwang, Joseph G Ibrahim, Vivek Jayaswa, Jouhyun Jeon, Zhicheng Ji, Deekshith Juvvadi, Sirkku Jyrkkiö, Kimberly Kanigel-Winner, Amin Katouzian, Marat D Kazanov, Shahin Khayyer, Dalho Kim, Agnieszka K Golinska, Devin Koestler, Fernanda Kokowicz, Ivan Kondofersky, Norbert Krautenbacher, Damjan Krstajic, Luke Kumar, Christoph Kurz, Matthew Kyan, Michael Laimighofer, Eunjee Lee, Wojciech Lesinski, Miaozhu Li, Ye Li, Qiuyu Lian, Xiaotao Liang, Minseong Lim, Henry Lin, Xihui Lin, Jing Lu, Mehrad Mahmoudian, Roozbeh Manshaei, Richard Meier, Dejan Miljkovic, Krzysztof Mnich, Nassir Navab, Elias C Neto, Yulia Newton, Subhabrata Pal, Byeongju Park, Jaykumar Patel, Swetabh Pathak, Alejandrina Pattin, Donna P Ankerst, Jian Peng, Anne H Petersen, Robin Philip, Stephen R Piccolo, Sebastian Pölsterl, Aneta Polewko-Klim, Karthik Rao, Xiang Ren, Miguel Rocha, Witold R. Rudnicki, Hyunnam Ryu, Hagen Scherb, Raghav Sehgal, Fatemeh Seyednasrollah, Jingbo Shang, Bin Shao, Howard Sher, Motoki Shiga, Artem Sokolov, Julia F Söllner, Lei Song, Josh Stuart, Ren Sun, Nazanin Tahmasebi, Kar-Tong Tan, Lisbeth Tomaziu, Joseph Usset, Yeeleng S Vang, Roberto Vega, Vitor Vieira, David Wang, Difei Wang, Junmei Wang, Lichao Wang, Sheng Wang, Yue Wang, Russ Wolfinger, Chris Wong, Zhenke Wu, Jinfeng Xiao, Xiaohui Xie, Doris Xin, Hojin Yang, Nancy Yu, Xiang Yu, Sulmaz Zahedi, Massimiliano Zanin, Chihao Zhang, Jingwen Zhang, Shihua Zhang, Yanchun Zhang, Hongtu Zhu, Shanfeng Zhu, Yuxin Zhu

Publikováno v: Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Lancet Oncol. 18, 132-142 (2017)
Guinney, J, Wang, T, Laajala, T D, Winner, K K, Bare, J C, Neto, E C, Khan, S A, Peddinti, G, Airola, A, Pahikkala, T, Mirtti, T, Yu, T, Bot, B M, Shen, L, Abdallah, K, Norman, T, Friend, S, Stolovitzky, G, Soule, H, Sweeney, C J, Ryan, C J, Scher, H I, Sartor, O, Xie, Y, Aittokallio, T, Zhou, F L, Costello, J C & Prostate Cancer Challenge DREAM Community 2017, ' Prediction of overall survival for patients with metastatic castration-resistant prostate cancer : development of a prognostic model through a crowdsourced challenge with open clinical trial data ', The Lancet: Oncology, vol. 18, no. 1, pp. 132-142 . https://doi.org/10.1016/S1470-2045(16)30560-5

Background: Improvements to prognostic models in metastatic castration-resistant prostate cancer have the potential to augment clinical trial design and guide treatment strategies. In partnership with Project Data Sphere, a not-for-profit initiative

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e29c71ca03dc8018abacbcb6b41b185
https://doi.org/10.1016/s1470-2045(16)30560-5